KevinJamesBielamowiczMD

Pediatric Hematology & Oncology • Little Rock, AR

Pediatric Neuro-Oncology

Physician

Join to view full profile

Dr. Bielamowicz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bielamowicz's full profile

Already have an account?

Office
Arkansas Children's Hospital, Arkansas Children's Northwest
1 Children's Way
Little Rock, AR 72202
Phone+1 501-263-2621

Education & Training

Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2012 - 2015
University of Arkansas for Medical Sciences (UAMS) College of MedicineChief Residency, Pediatrics, 2011 - 2012
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Pediatrics, 2008 - 2011
University of Texas Southwestern Medical SchoolClass of 2008

Certifications & Licensure

AR State Medical License 2016 - 2026
TX State Medical License 2015 - 2018
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Start of enrollment: 2019 Sep 29
Active, not recruiting
Phase 2
Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children Start of enrollment: 2016 Feb 16
Completed
Phase 1
Roles: Principal Investigator, Contact
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Start of enrollment: 2015 Sep 01
Active, not recruiting
Phase 4
Roles: Contact
A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Start of enrollment: 2021 Feb 24
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy Start of enrollment: 2023 Feb 23
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors Start of enrollment: 2020 Sep 01
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures.
Kevin Bielamowicz, Peter Dimitrion, Oussama Abla, Simon Bomken, Patrick Campbell
Cancer. 2024-07-15
1 citations
Central nervous system embryonal tumors with EWSR1-PLAGL1 rearrangements reclassified as INI-1 deficient tumors at relapse.
Kevin J Bielamowicz, Mary Beth Littrell, Gregory W Albert, Lora S Parker, Sateesh Jayappa
Journal of Neuro-Oncology. 2024-06-01
6 citations
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study.
Ayse Bahar Ercan, Melyssa Aronson, Nicholas R Fernandez, Yuan Chang, Adrian Levine
The Lancet. Oncology. 2024-05-01

Abstracts/Posters

Establishing a Novel in Vitro Informed Precision Clinical Trial Pathway for Refractory Pediatric Leukemia
Kevin J. Bielamowicz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019